Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss

Loading news article.

Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss | WAPE

Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss

Article summary

Related companies

Comments —